News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Monteris® Medical First-In-Humans Trial Published

Al's Comment:

 This is a very small trial but shows that this new treatment may be worthwhile. It is a new type of minimally invasive laser surgery. It is already approved and in use in a few centers across the country. Go to http://www.monteris.com/ for details.


Posted on: 05/04/2013

Monteris® Medical First-In-Humans Trial Published

 

BusinessWire · Apr. 29, 2013 | Last Updated: Apr. 29, 2013 11:21 AM ET

Monteris Medical announced that their First-In-Humans clinical trial with the NeuroBlate® System for neurosurgical ablation has been published in the Journal of Neurosurgery. This study was a thermal dose-escalation trial to assess the safety and efficacy of the NeuroBlate System to treat recurrent Glioblastoma Multiforme (GBM) brain tumors. "Although not a large trial, it is significant as a foundation on which to build the clinical data needed for broad technology adoption," said Dr. Andrew Sloan, Director of the Brain Tumor & Neuro-Oncology Center, Vice Chairman of Neurosurgery and holder of the Peter D. Cristal Chair of Neurosurgical Oncology at University Hospitals-Case Medical Center and an investigator in the trial. “Furthermore, this is the first contemporary report of a trial using laser interstitial thermal therapy for gliomas, which are a particularly difficult type of brain tumor to treat and have a very poor prognosis.”

Ten patients with recurrent or progressive GBM who had failed standard therapy (radiotherapy with or without chemotherapy) and were deemed to have “inoperable recurrent GBM” were enrolled in the trial. The patients were divided into three groups defined by the amount of laser energy (dose) delivered to the tumor with the NeuroBlate System. “The median survival time of 316 days seen in this cohort of patients is encouraging, as compared to the 90-150 day median survival typically observed for recurrent GBM’s,” stated Dr. Gene Barnett, Professor and Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Vice-Chair of Neurosurgery and Rose Ella Burkhardt Chair of Neuro-Oncology Research at Cleveland Clinic. “These patients not only have a poor prognosis, but have limited treatment options. We believe that the NeuroBlate System will be an important tool for neurosurgeons and will allow us to treat patients who might otherwise have few options.” Dr. Barnett was the Principal Investigator in the trial and is Consulting Medical Director for Monteris.

The full article is available on the Journal of Neurosurgery website www.thejns.org/action/showAllForthcomingToc

About Monteris Medical

Monteris® Medical is a privately held medical device company dedicated to the development of innovative MRI-guided, laser-based brain treatments. Monteris® Medical markets the NeuroBlate® System, a neurosurgical device providing controlled ablation for difficult-to-treat brain lesions. www.monteris.com

 

Contacts

Monteris Medical
Kathryn Meintsma, 612-961-7541
kmeintsma@monteris.com

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740